
Maintenance olaparib Improves Progression-Free Survival in Phase III Clinical Trial
(October 23, 2018) Olaparib, or Lynparza, was shown to increase progression-free survival (PFS) by almost three years in an ongoing trial known as SOLO-1. The women in the study are … Continued